Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation

LEO Pharma

Status: Completed

Conditions: Plaque Psoriasis; Psoriasis Vulgaris

Treatments: Drug: Daivobet® Gel

Study type: Observational

Funder types: Industry

Identifiers

NCT01707368

DE-Daivobet-longterm-NIS-2012

Details and patient eligibility

About

The purpose of this observational study is to document the course of disease and relapse management during treatment with Daivobet® Gel under consideration of patient's individual application habits under daily use conditions.

Enrollment: 561 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with light to moderate psoriasis vulgaris of trunk and extremities and treatment with Daivobet® Gel was planned anyway.
• Minimum of 3 years diagnosed psoriasis vulgaris.

Exclusion criteria

• Previous therapy with Daivobet® Gel
• Systemic therapy of psoriasis vulgaris
• Contraindications of Daivobet® Gel in the German package insert
• people that are incapable to give free consent

Trial design

561 participants in 1 patient group

all eligible patients

Description:

Daivobet® Gel once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.

Treatment:

Drug: Daivobet® Gel